Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy

被引：52

作者：

Arvedson, Tara ^{[1
]}

Bailis, Julie M. ^{[1
]}

Britten, Carolyn D. ^{[2
]}

Klinger, Matthias ^{[3
]}

Nagorsen, Dirk ^{[2
]}

Coxon, Angela ^{[4
]}

Egen, Jackson G. ^{[1
]}

Martin, Flavius ^{[1
]}

机构：

[1] Amgen Inc, Amgen Res, San Francisco, CA 94080 USA

[2] Amgen Inc, Amgen Global Dev, Thousand Oaks, CA 91320 USA

[3] Amgen Res Munich GmbH, Munich, Germany

[4] Amgen Inc, Amgen Res, Thousand Oaks, CA 91320 USA

来源：

ANNUAL REVIEW OF CANCER BIOLOGY | 2022年 / 6卷

关键词：

blinatumomab; combination therapy; cytokine release syndrome; solid tumors; T cell engager; tumor-associated antigen; SINGLE-CHAIN ANTIBODY; ACUTE LYMPHOBLASTIC-LEUKEMIA; MALIGNANT ASCITES; BLINATUMOMAB; CANCER; 1ST-IN-HUMAN; CATUMAXOMAB; MULTICENTER; CONSTRUCTS; BLOCKADE;

D O I：

10.1146/annurev-cancerbio-070620-104325

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

T cell engagers (TCEs) are targeted immunotherapies that have emerged as a promising treatment to redirect effector T cells for tumor cell killing. The strong therapeutic value of TCEs, established by the approval of blinatumomab for the treatment of B cell precursor acute lymphoblastic leukemia, has expanded to include other hematologic malignancies, as well as some solid tumors. Successful clinical development of TCEs in solid tumors has proven challenging, as it requires additional considerations such as the selectivity of target expression, tumor accessibility, and the impact of the immunosuppressive tumor microenvironment. In this review, we provide a brief history of blinatumomab, summarize learnings from TCEs in hematologic malignancies, and highlight results from recent TCE trials in solid tumors. Additionally, we examine approaches to improve the efficacy and safety of TCEs in solid tumors, including therapeutic combinations to increase the depth and durability of response.

引用

页码：17 / 34

页数：18

共 101 条

[1] Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia [J].

Aldoss, Ibrahim ;

Uy, Geoffrey L. ;

Vey, Norbert ;

Emadi, Ashkan ;

Sayre, Peter H. ;

Walter, Roland B. ;

Foster, Matthew C. ;

Arellano, Martha L. ;

Godwin, John E. ;

Wieduwilt, Matthew J. ;

Byrne, Michael T. ;

Michaelis, Laura C. ;

Stiff, Patrick J. ;

Carrabba, Matteo Giovanni ;

Chevalier, Patrice ;

Gyan, Emmanuel ;

Recher, Christian ;

Advani, Anjali S. ;

Wermke, Martin ;

Erba, Harry P. ;

Ciceri, Fabio ;

Huls, Geert ;

Jongen-Lavrencic, Mojca ;

Topp, Max S. ;

Curti, Antonio ;

Ravandi, Farhad ;

Rettig, Michael P. ;

Muth, John ;

Collins, Mary Beth ;

Timmeny, Erin ;

Guo, Kuo ;

Zhao, Jian ;

Tran, Kathy ;

Kaminker, Patrick ;

Patel, Priyanka ;

Bakkacha, Ouiam ;

Curtis, Teia ;

Jacobs, Kenneth ;

Kostova, Maya ;

Seiler, Jennifer ;

Lowenberg, Bob ;

Rutella, Sergio ;

Bonvini, Ezio ;

Davidson-Moncada, Jan K. ;

DiPersio, John F. .

BLOOD, 2020, 136

[2]

Argiles G, 2017, ANN ONCOL, V28, P151

[3]

attaruzza F, 2020, J IMMUNOTHER CANCER, V8

[4] Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy [J].

Bannerji, Rajat ;

Allan, John N. ;

Arnason, Jon E. ;

Brown, Jennifer R. ;

Advani, Ranjana ;

Ansell, Stephen M. ;

O'Brien, Susan M. ;

Duell, Johannes ;

Martin, Peter ;

Joyce, Robin M. ;

Li, Jingjin ;

Flink, Dina M. ;

Zhu, Min ;

Weinreich, David M. ;

Yancopoulos, George D. ;

Sirulnik, Andres ;

Chaudhry, Aafia ;

Ambati, Srikanth R. ;

Topp, Max S. .

BLOOD, 2020, 136

[5] Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].

Bargou, Ralf ;

Leo, Eugen ;

Zugmaier, Gerhard ;

Klinger, Matthias ;

Goebeler, Mariele ;

Knop, Stefan ;

Noppeney, Richard ;

Viardot, Andreas ;

Hess, Georg ;

Schuler, Martin ;

Einsele, Hermann ;

Brandl, Christian ;

Wolf, Andreas ;

Kirchinger, Petra ;

Klappers, Petra ;

Schmidt, Margit ;

Riethmueller, Gert ;

Reinhardt, Carsten ;

Baeuerle, Patrick A. ;

Kufer, Peter .

SCIENCE, 2008, 321 (5891) :974-977

[6] Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors [J].

Belmontes, Brian ;

Sawant, Deepali, V ;

Zhong, Wendy ;

Tan, Hong ;

Kaul, Anupurna ;

Aeffner, Famke ;

O'Brien, Sarah A. ;

Chun, Matthew ;

Noubade, Rajkumar ;

Eng, Jason ;

Ma, Hayley ;

Muenz, Markus ;

Li, Peng ;

Alba, Benjamin M. ;

Thomas, Melissa ;

Cook, Kevin ;

Wang, Xiaoting ;

DeVoss, Jason ;

Egen, Jackson G. ;

Nolan-Stevaux, Olivier .

SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (608)

[7]

Bendell JC, 2020, J CLIN ONCOL, V38

[8] CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory [J].

Benonisson, Hreinn ;

Altintas, Isil ;

Sluijter, Marjolein ;

Verploegen, Sandra ;

Labrijn, Aran F. ;

Schuurhuis, Danita H. ;

Houtkamp, Mischa A. ;

Verbeek, J. Sjef ;

Schuurman, Janine ;

van Hall, Thorbald .

MOLECULAR CANCER THERAPEUTICS, 2019, 18 (02) :312-322

[9] Understanding the tumor immune microenvironment (TIME) for effective therapy [J].

Binnewies, Mikhail ;

Roberts, Edward W. ;

Kersten, Kelly ;

Chan, Vincent ;

Fearon, Douglas F. ;

Merad, Miriam ;

Coussens, Lisa M. ;

Gabrilovich, Dmitry I. ;

Ostrand-Rosenberg, Suzanne ;

Hedrick, Catherine C. ;

Vonderheide, Robert H. ;

Pittet, Mikael J. ;

Jain, Rakesh K. ;

Zou, Weiping ;

Howcroft, T. Kevin ;

Woodhouse, Elisa C. ;

Weinberg, Robert A. ;

Krummel, Matthew F. .

NATURE MEDICINE, 2018, 24 (05) :541-550

[10]

Borghaei H, 2020, SOC IMMUNOTHERAPY CA

← 1 2 3 4 5 6 7 8 9 10 →